Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Free Cash Flow (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Free Cash Flow for 5 consecutive years, with -$7.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 60.33% to -$7.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$34.1 million, a 58.0% increase, with the full-year FY2024 number at -$72.3 million, down 12.43% from a year prior.
  • Free Cash Flow was -$7.4 million for Q3 2025 at Lyra Therapeutics, down from -$6.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $4.2 million in Q2 2021 to a low of -$22.8 million in Q1 2024.
  • A 5-year average of -$12.2 million and a median of -$12.2 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 300.65% in 2022, then soared 66.54% in 2025.
  • Lyra Therapeutics' Free Cash Flow stood at -$12.4 million in 2021, then rose by 1.52% to -$12.2 million in 2022, then crashed by 64.84% to -$20.1 million in 2023, then surged by 43.8% to -$11.3 million in 2024, then soared by 34.82% to -$7.4 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Free Cash Flow are -$7.4 million (Q3 2025), -$6.6 million (Q2 2025), and -$8.8 million (Q1 2025).